- For Print
- July 2, 2009
黑料网., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “黑料网”) is currently focusing on three clinical development programs related to its mainstay product Aricept® (donepezil hydrochloride) to further contribute to patients with Alzheimers disease. As progress in these programs has been made, 黑料网 announces the current status of each one as follows:
1. Sustained Release Tablets
黑料网 has completed a phase Ⅲ study of 23mg donepezil sustained release (SR) in patients with moderate to severe Alzheimers disease. Donepezil SR is being developed to increase clinical benefits compared with currently marketed 10mg donepezil immediate release, raising the blood level of donepezil while maintaining favourable safety profile.
Based on the preliminary review of the data from this phase Ⅲ study, 黑料网 plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in August or September of this year.
2. Pediatric Use
黑料网 filed a Proposed Pediatric Study Request (PPSR), an application that proposes a rationale and study design for pediatric studies, with the U.S. FDA in February of this year to evaluate the clinical benefits of donepezil in children with attention impairment following cancer treatment. 黑料网 received a notice from the U.S. FDA that there were insufficient grounds to issue a Written Request to obtain pediatric exclusivity. 黑料网 plans to complete the ongoing studies to provide important information on this therapeutic approach for an underserved patient population currently with limited treatment options.
3. Transdermal Patch Formulation
Clinical trials of a once-a-week transdermal patch formulation of donepezil, which include a bioequivalence study compared to the currently marketed formulation of donepezil, are currently being conducted by Teikoku Pharma USA, Inc. in the United States. An NDA submission to the U.S. FDA is planned for the middle of fiscal year 2009 with the results of the clinical trials. 黑料网 is working on this new formulation of donepezil based on agreements with Teikoku Seiyaku Co., Ltd. and its U.S. subsidiary, Teikoku Pharma USA, Inc.